Myomics recognized for transforming cardiac MRI into a virtual biopsy
Phantomics, a leading medical AI company, has been awarded the KHF 2025 Innovation Award for its groundbreaking cardiac MRI analysis solution, Myomics.
Myomics is the world’s first AI solution to offer “virtual biopsy” capabilities for the heart. It analyzes cardiac MRI data—including LGE, T1/T2 mapping, and blood flow imaging—to deliver diagnostic accuracy comparable to tissue biopsy, without invasive procedures.
The solution reduces analysis time from over 30 minutes to under 5 minutes, while improving diagnostic accuracy by 1.8 times. It enables early detection of conditions such as myocarditis, myocardial infarction, heart failure, and amyloidosis, even before symptoms appear.
The KHF Innovation Award, hosted by the Korean Hospital Association, recognizes technologies that advance the healthcare industry and support global competitiveness. Phantomics’ win highlights the clinical value and innovation of its AI platform.
CEO Pan Ki Kim stated, “Our mission is to save hearts. Myomics is not just a support tool—it’s a clinical solution that improves patient safety and diagnostic precision.”
Read the article (Medical Times)
Myomics recognized for transforming cardiac MRI into a virtual biopsy
Phantomics, a leading medical AI company, has been awarded the KHF 2025 Innovation Award for its groundbreaking cardiac MRI analysis solution, Myomics.
Myomics is the world’s first AI solution to offer “virtual biopsy” capabilities for the heart. It analyzes cardiac MRI data—including LGE, T1/T2 mapping, and blood flow imaging—to deliver diagnostic accuracy comparable to tissue biopsy, without invasive procedures.
The solution reduces analysis time from over 30 minutes to under 5 minutes, while improving diagnostic accuracy by 1.8 times. It enables early detection of conditions such as myocarditis, myocardial infarction, heart failure, and amyloidosis, even before symptoms appear.
The KHF Innovation Award, hosted by the Korean Hospital Association, recognizes technologies that advance the healthcare industry and support global competitiveness. Phantomics’ win highlights the clinical value and innovation of its AI platform.
CEO Pan Ki Kim stated, “Our mission is to save hearts. Myomics is not just a support tool—it’s a clinical solution that improves patient safety and diagnostic precision.”
Read the article (Medical Times)